NewslettersPulmonary Cell NewsBRAF/MEK Inhibition in NSCLC: Mechanisms of Resistance and How to Overcome ItBy Bob - June 23, 20220166Investigators discuss inhibition of BRAF and its downstream effector MEK which constitutes a therapeutic strategy for a subset of patients with NSCLC and is associated with clinical benefit.[Clinical and Translational Oncology]Abstract